BridgeBio Oncology Therapeutics, Inc.: 5%+ holders

BridgeBio Oncology Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-07-24. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Helix Holdings II LLC

Item 4 is hereby amended and supplemented as follows: As previously disclosed, on February 28, 2025, the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") entered into a Business Combination Agreement (as amended on June 20, 2025, the "Business Combination Agreement") with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics, "Legacy BBOT"), and Helix II Merger Sub, Inc. ("Merger Sub"), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, the Domestication of Helix as a Delaware corporation would occur, followed by the Merger of Merger Sub with and into Legacy BBOT. Prior to the Business Combination, Ms. Chen was the Chairwoman and Chief Executive Officer of the Issuer, a shareholder of the Issuer, and a shareholder of Legacy BBOT. On August 11, 2025, the Domestication occurred. Immediately prior to the Domestication, Sponsor forfeited 307,874 Sponsor Forfeited Shares and subsequently converted an aggregate of 4,172,126 Helix Class B ordinary shares held by it, in each case pursuant to the terms of the Support Agreement. Upon the completion of the Domestication, each Helix Class A ordinary share held by the Reporting Persons automatically converted into one share of Common Stock of the Issuer, on a one-for-one basis. On August 11, 2025, the PIPE Investments closed and the Reporting Persons purchased an aggregate of 6,998,031 shares of Common Stock at a price per share of $10.7173, representing the …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-08-13; the filing has the rest

BridgeBio Pharma LLC

The Reporting Persons acquired the Shares for investment purposes in the ordinary course of business. Immediately following the Effective Time of the Business Combination, Neil Kumar, Ph.D., Chief Executive Officer and a member of the board of directors of BBIO, and Frank P. McCormick, Ph.D., F.R.S., D.Sc., Chairman of Oncology and a member of the board of directors of BBIO, were appointed to serve as directors of the Issuer. As a result of their positions, Drs. Kumar and McCormick may, from time to time, engage in discussions with the Issuer's board of directors, management, or other stockholders regarding matters relating to the Issuer's business, operations, governance, strategy, or capital structure. These discussions may include, but are not limited to: (i) the acquisition or disposition of securities of the Issuer; (ii) potential changes to the Issuer's board or management; (iii) strategic transactions, including mergers, acquisitions, or dispositions; or (iv) other matters described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may also participate in discussions regarding the Issuer's strategic direction, including potential financing activities, collaborations, or licensing transactions. In connection with the foregoing, and as may be appropriate from time to time, the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to their investment in the Issuer, including, …The first part of Item 4 of the SCHEDULE 13D filed 2025-08-18; the filing has the rest

Bihua Chen

Item 4 is hereby amended and supplemented as follows: On July 1, 2026, Sponsor distributed 4,528,186 shares of Common Stock, pro rata, to its members for no consideration. Following such transaction, Sponsor holds no shares of Common Stock. As a result of Sponsor's pro rata distribution of shares to its members, (i) Fund III, a member of Sponsor, acquired 2,692,459 shares of Common Stock; (ii) Fund V, a member of Sponsor, acquired 1,704,862 shares of Common Stock; and (iii) Master Fund, a member of Sponsor, acquired 130,865 shares of Common Stock.Item 4 of the SCHEDULE 13D/A filed 2026-07-06

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes